Skip to main content
CHRS
NASDAQ Life Sciences

Coherus Oncology Solicits Votes for Employee Stock Option Repricing Proposal

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.79
Mkt Cap
$276.05M
52W Low
$0.71
52W High
$2.616
52W Position info
152% above low
Off High info
32% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

CHRS has more than doubled off its 52-week low of $0.71.

Summary

Coherus Oncology is actively soliciting shareholder votes for a proposal to reprice employee stock options with strike prices of $5 and above down to the closing price on the annual meeting date, aiming to re-incentivize employees.


Key Events · Corporate Governance and Compliance · CHRS

  • Option Repricing Proposal

    The company is soliciting votes for a proposal to reprice employee stock options with strike prices of $5 and above down to the closing price on the May 27, 2026, Annual Shareholder Meeting date.

  • Employee Solicitation

    The Chief Human Resources Officer sent an email to all employees, urging them to vote "FOR" the proposals, specifically highlighting the option repricing.

  • Potential Dilution & Retention

    If approved, this proposal would significantly re-incentivize employees by making deeply underwater options valuable again, but it also implies increased potential dilution for existing shareholders.


Analysis · CHRS · Life Sciences

This DEFA14A filing serves as a direct appeal to employees to vote in favor of a significant proposal at the upcoming Annual Shareholder Meeting. The core of the proposal is to reprice existing employee stock options that have strike prices of $5 or more, adjusting them down to the stock's closing price on the meeting date. Given the current stock price of $1.79, this would significantly reduce the exercise price for many underwater options, effectively re-incentivizing employees. While this move is positive for employee retention and morale, especially following the company's recent strategic pivot to oncology, it introduces potential future dilution for existing shareholders. Investors should monitor the outcome of this vote and the potential impact on the company's share count and compensation expenses.

At the time of this filing, CHRS was trading at $1.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $276M. The 52-week trading range was $0.71 to $2.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CHRS - Latest Insights

CHRS
Aug 05, 2026, 5:14 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.38
Real-time Price: $1.31 info
Change: -$0.0719 (-5%) info
Market Cap: $196.216M info
CHRS
Aug 05, 2026, 4:50 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $1.41
Real-time Price: $1.31 info
Change: -$0.1034 (-7%) info
Market Cap: $196.216M info
CHRS
Aug 05, 2026, 4:43 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $1.31 info
Change: -$0.1034 (-7%) info
Market Cap: $196.216M info
CHRS
Jun 23, 2026, 2:00 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.49
Real-time Price: $1.31 info
Change: -$0.1769 (-12%) info
Market Cap: $196.216M info
CHRS
Jun 01, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.64
Real-time Price: $1.31 info
Change: -$0.3319 (-20%) info
Market Cap: $196.216M info